Common Variable Immunodeficiency (CVID) is a rare primary immunodeficiency disorder characterized by low levels of antibodies, leading to increased susceptibility to infections. The prevalence of CVID varies across different populations, ranging from approximately 1 in 25,000 to 1 in 50,000 individuals. It affects both males and females equally and can manifest at any age, although most cases are diagnosed in adulthood. CVID is often underdiagnosed or misdiagnosed due to its diverse clinical presentation. Early recognition and proper management are crucial for improving the quality of life for individuals with CVID.
Common Variable Immunodeficiency (CVID) is a rare primary immunodeficiency disorder characterized by a deficiency in the production of antibodies, leaving individuals more susceptible to infections. The prevalence of CVID varies across different populations and geographical regions.
While it is challenging to determine the exact prevalence of CVID due to underdiagnosis and misdiagnosis, studies estimate that it affects approximately 1 in 25,000 to 1 in 50,000 individuals worldwide. However, it is important to note that these figures may not capture the full extent of the disorder, as milder cases can go undetected.
CVID can occur at any age, but it is most commonly diagnosed in adolescence or early adulthood. Both males and females are affected equally. The disorder is often characterized by recurrent respiratory tract infections, gastrointestinal issues, autoimmune diseases, and an increased risk of certain cancers.
Early diagnosis and appropriate management are crucial for individuals with CVID to prevent complications and improve their quality of life. Treatment typically involves regular infusions of immunoglobulins to boost antibody levels and prevent infections. Additionally, antibiotics, anti-inflammatory drugs, and other supportive therapies may be prescribed based on individual needs.